Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 20% IN WATER vs MANNITOL 15% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.
Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
Reduction of intracranial pressure and cerebral edema,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (as an adjunct),Treatment of dialysis disequilibrium syndrome,Management of oliguric phase of acute renal failure
Reduction of elevated intracranial pressure (FDA-approved),Promotion of diuresis in acute renal failure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Irrigant in transurethral prostatic resection (FDA-approved),Enhancement of urinary excretion of toxic substances (off-label)
1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.
Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.
0.25–1.5 hours (15–90 minutes) in patients with normal renal function. In oliguric or anuric patients, half-life is markedly prolonged, up to 36 hours, due to reduced clearance.
Terminal elimination half-life approximately 0.5–1 hour in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Not metabolized; excreted unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration, with a small amount reabsorbed in the proximal tubule.
Primarily renal excretion as unchanged drug. Over 90% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized in the liver; negligible biliary/fecal elimination.
Renal: >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<2%).
Negligible (<5%); essentially unbound.
Negligible protein binding (<0.5%); no specific binding proteins identified.
Approximately 0.3–0.6 L/kg. Mannitol distributes primarily in extracellular fluid; does not cross cell membranes readily unless administered in large doses or under pathological conditions (e.g., disrupted blood-brain barrier). Increased Vd may indicate expanded extracellular volume.
Approximately 0.5–0.7 L/kg (confined to extracellular fluid space; does not cross cell membranes significantly).
Intravenous: 100%. Oral: Not applicable; not administered orally due to poor absorption and osmotic diarrhea. Other routes (e.g., subcutaneous or intramuscular) are not clinically relevant.
Intravenous: 100% (only route used clinically); no oral bioavailability due to poor absorption and osmotic diarrhea.
Contraindicated in anuria or severe renal impairment (Cr Cl < 30 m L/min). Use with caution if Cr Cl < 50 m L/min; monitor serum osmolality and urine output. No specific dose adjustment guidelines exist; consider alternative therapy.
Contraindicated in anuria. GFR <15 m L/min: avoid use. GFR 15-30 m L/min: use with caution, monitor serum osmolarity and electrolytes. No specific dose adjustment for mild-moderate renal impairment; clinical judgment required.
No specific adjustment required for hepatic impairment. Use with caution in severe liver disease due to risk of fluid overload.
No specific dose adjustment for hepatic impairment; monitor for fluid and electrolyte disturbances.
For reduction of intracranial pressure: 0.25-1 g/kg (1.25-5 m L/kg of 20% solution) intravenously over 30-60 minutes, repeated every 6-8 hours as needed. Maximum dose: 2 g/kg/day.
Intravenous: 1-2 g/kg as a 15-20% solution over 30-60 minutes. For acute renal failure: test dose of 0.2 g/kg IV over 30 minutes; if urine output >1 m L/kg/hr, continue with 0.5-1 g/kg every 4-6 hours. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. Maximum infusion rate: 60 g/hour.
Start at lower end of dosing range (0.5 g/kg) due to increased risk of renal impairment and hypovolemia. Monitor serum electrolytes, osmolality, and renal function closely. Avoid in patients with significant cardiovascular disease.
Start at lower end of dosing range; monitor renal function, fluid balance, and electrolytes closely due to age-related decreased renal function and higher risk of volume overload.
No FDA boxed warning.
None.
Risk of pulmonary edema or congestive heart failure due to volume expansion,May cause electrolyte imbalance (e.g., hyponatremia, hyperkalemia) and dehydration,Monitor renal function; contraindicated in anuria or severe renal impairment,May increase intracranial pressure rebound effect,Use with caution in patients with severe hypovolemia or electrolyte disorders,Intravenous administration requires careful monitoring of fluid and electrolyte status
Use with caution in patients with heart failure, pulmonary congestion, or renal impairment due to risk of fluid overload and electrolyte disturbances.,Monitor serum electrolytes, osmolality, and renal function during therapy.,Avoid in patients with anuria due to severe renal disease.,Rapid infusion may cause circulatory overload resulting in hyponatremia and hyperosmolality.
Anuria due to severe renal disease,Severe pulmonary congestion or pulmonary edema,Severe dehydration,Intracranial hemorrhage (unless during craniotomy) or active intracranial bleeding,Hypersensitivity to mannitol or any component of the formulation
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Dehydration,Hypersensitivity to mannitol
No significant food interactions. However, patients on this therapy often have restricted fluid and electrolyte intake; follow prescribed dietary restrictions, especially regarding sodium and fluid intake, as directed by the healthcare team.
No specific food interactions. Maintain adequate hydration unless contraindicated. Avoid excessive salt intake as it may counteract diuretic effect.
Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretical risk of fetal osmotic shifts, but no well-controlled studies exist. In the second and third trimesters, use may cause fetal dehydration and electrolyte disturbances. Due to its limited indications in pregnancy (e.g., for elevated intracranial pressure), the risk-benefit must be carefully evaluated. Mannitol is assigned to FDA Pregnancy Category C.
Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In the first trimester, risks are unknown; in second and third trimesters, maternal administration may cause fetal electrolyte disturbances due to osmotic diuresis.
It is unknown if mannitol is excreted in human milk. Given its high molecular weight and low lipid solubility, excretion is likely minimal but not confirmed. Caution is advised; use only if clearly needed. M/P ratio is not available.
It is not known whether mannitol is excreted in human milk. The M/P ratio is not established. Caution should be exercised when mannitol is administered to a nursing woman. The drug should be used only if clearly needed, considering the potential for adverse effects in nursing infants such as osmotic diuresis and electrolyte imbalance.
Pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may require dose adjustments. However, mannitol dosing is titrated to effect (e.g., urine output, serum osmolality). Pregnancy may reduce the duration of action. Monitor clinical response more frequently and adjust dose as needed to maintain desired osmolality and avoid toxicity.
Pregnancy may alter pharmacokinetics of mannitol due to increased plasma volume and renal blood flow, potentially increasing clearance. However, specific dose adjustments are not recommended. The usual adult dose (50-200 g per 24 hours) may be used with careful monitoring of maternal hydration status, urine output, and serum osmolality to avoid volume depletion or overload. No standard dose reduction is indicated.
Monitor serum osmolarity and sodium levels closely; risk of hypematremia and hyperosmolality, especially in renal impairment. Use with caution in patients with congestive heart failure or pulmonary congestion. Administer via central line to avoid phlebitis. In acute renal failure, a test dose of 0.2 g/kg over 3-5 minutes may be given; if urine flow increases > 40 m L/h, full therapy can be initiated. Taper abruptly to avoid rebound intracranial hypertension. Contraindicated in anuria, intracranial hemorrhage, severe dehydration, and glucose intolerance (use with caution in diabetics).
Mannitol 15% is an osmotic diuretic used primarily for reduction of intracranial pressure (ICP) and cerebral edema. In emergency settings, administer via IV bolus (0.25-1 g/kg) over 30-60 minutes; onset of ICP reduction occurs within 15-30 minutes. Monitor serum osmolality and avoid if >320 m Osm/L. Use with caution in acute tubular necrosis. Can cause transient volume expansion followed by diuresis; watch for pulmonary edema in heart failure patients. Crystallization may occur at low temperatures; warm and inspect before use.
This medication may cause you to urinate frequently; it is used to reduce brain swelling or to promote urine output.,You may experience headache, nausea, blurred vision, or thirst; report these to your healthcare provider.,Your fluid intake and output, as well as blood tests (electrolytes, kidney function), will be monitored closely.,Do not stop taking this medication abruptly without consulting your doctor; sudden withdrawal may worsen your condition.,Inform your doctor if you have heart disease, kidney disease, or diabetes.,This medication is given intravenously, usually in a hospital setting.
This medication is given intravenously to reduce swelling in the brain.,You may experience increased urination, headache, or dry mouth.,Report any chest pain, difficulty breathing, or unusual swelling.,Do not stop or change the infusion rate without medical advice.,Tell your doctor if you have kidney disease, heart failure, or electrolyte imbalances.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 20% IN WATER vs MANNITOL 15% IN PLASTIC CONTAINER, answered by our medical review team.
OSMITROL 20% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.. MANNITOL 15% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 20% IN WATER and MANNITOL 15% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 20% IN WATER is: 1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.. The standard adult dose of MANNITOL 15% IN PLASTIC CONTAINER is: Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 20% IN WATER and MANNITOL 15% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 20% IN WATER is classified as Category C. Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretica. MANNITOL 15% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.